HY Revenue Rmb3.76 Billion Versus Rmb3.11 Billion
29/08/2022 11:20
Shenzhen Hepalink Pharmaceutical Group Co Ltd 002399.SZ :
* SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO LTD - HY
REVENUE
RMB3.76 BILLION VERSUS RMB3.11 BILLION
* SHENZHEN HEPALINK PHARMACEUTICAL - HY PROFIT ATTRIBUTABLE
RMB511.1 MILLION VERSUS RMB338.2 MILLION
Source text for Eikon: ID:
Further company coverage: 002399.SZ
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA